Phillip Pymm

TL;DR: It is found that S-specific antibodies, memory B cells and cTFH are consistently elicited after SARS-CoV-2 infection, demarking robust humoral immunity and positively associated with plasma neutralizing activity, suggesting that vaccines might require strategies to selectively target the most potent neutralizing epitopes.

TL;DR: In this article, high affinity nanobodies from alpacas immunized with coronavirus spike and receptor-binding domains (RBD) were identified that disrupted RBD engagement with the human receptor angiotensin-converting enzyme 2 (ACE2) and potently neutralized SARS-CoV-2.

TL;DR: In this paper, the authors developed a rapid, high-throughput, multiplex assay able to assess the inhibitory response of antibodies to 24 RBD natural variants simultaneously, which can be implemented as a rapid surrogate assay for functional cell-based serological methods to measure the SARS-CoV-2 neutralizing capacity.

TL;DR: In this article, a diverse panel of 91 human, neutralizing monoclonal antibodies provides an in-depth structural and phenotypic definition of receptor binding domain antigenic sites on the viral spike.

TL;DR: Both qualitative and quantitative features of B and T cell immunity to spike constitute informative biomarkers of the protective potential of novel SARS-CoV-2 vaccines.